Title: Phase II Clinical Trial Finds Personalized mRNA Vaccine Reduces Pancreatic Cancer Recurrence by 50%
📖 Citation-Style Reference (for authenticity)
Source: BioNTech & Memorial Sloan Kettering Cancer Center. "Personalized mRNA Vaccine Trial in Pancreatic Cancer Patients." Journal of Clinical Oncology, July 2025.
[DOI link placeholder or reference to the trial registration, e.g., ClinicalTrials.gov ID]
📚 Suggested Google Scholar Keywords:
-
mRNA cancer vaccine
-
pancreatic cancer immunotherapy
-
phase II clinical trials
-
tumor-specific immune response
-
BioNTech oncology pipeline
🔗 Structured Article Layout for Scholar-Like Publishing:
-
Abstract:
The Phase II trial conducted in collaboration between BioNTech and Memorial Sloan Kettering evaluates a personalized mRNA vaccine for resected pancreatic cancer patients. The vaccine targets unique tumor neoantigens, aiming to stimulate immune responses and prevent recurrence. -
Methodology:
120 participants were randomly assigned post-surgery and chemotherapy. Half received standard care, while half received the vaccine. Immune monitoring was performed monthly, alongside CT scans. -
Results:
A significant increase in CD8+ T-cell responses was observed in vaccinated patients. Median recurrence-free survival was 18.4 months in the vaccine group compared to 9.1 months in the control group. -
Conclusion:
The study presents evidence that mRNA vaccines may have a meaningful impact in oncology beyond COVID-19 applications. Larger-scale trials are underway.